Global Schizophrenia Drugs Market Analysis 2016-2017 and Forecasts to 2022 - A $7.9 Billion Market Opportunity - ResearchAndMarkets.com

DUBLIN--()--The "Schizophrenia Drugs Market Analysis, By Therapeutic Class (Second-Generation, Third-Generation Antipsychotics), By Treatment (Oral, Injectables), By Major Markets, And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global schizophrenia drugs market is expected to be valued at USD 7.9 billion by 2022.

The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

A few of the prominent players operating in this industry are Johnson & Johnson, Bristol-Myers Squibb/Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan and Pfizer.

Companies Mentioned

  • Johnson & Johnson
  • Bristol-Myers Squibb and Company
  • Otsuka Pharmaceuticals
  • AstraZeneca
  • Eli Lilly
  • Alkermes
  • Sumitomo Dainippon Pharma
  • Pfizer
  • Vanda Pharmaceuticals
  • Allergan (Forest Labs)
  • Geodon Ritcher

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Market Overview

Chapter 5 Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/jpt8m3/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs